Samsung Bioepis’ Humira biosimilar launches in EUSamsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Share XSamsung Bioepis’ Humira biosimilar launches in EUhttps://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/
Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
Sandoz free to launch Humira biosimilar following AbbVie dealNovartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) Share XSandoz free to launch Humira biosimilar following AbbVie dealhttps://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/
Celltrion’s Rituxan biosimilar gets glowing review ahead of key meetingReviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead Share XCelltrion’s Rituxan biosimilar gets glowing review ahead of key meetinghttps://pharmaphorum.com/news/celltrions-rituxan-biosimilar-gets-glowing-review-ahead-of-key-meeting/
NHS to reimburse Gilead’s CAR-T in adultsThe first CAR-T therapy aimed at adults with lymphoma is to be reimbursed in England after manufacturer Gilead Share XNHS to reimburse Gilead’s CAR-T in adultshttps://pharmaphorum.com/news/nhs-to-reimburse-gileads-car-t-in-adults/
Merck & Co signs biosimilars deal for US veteransMerck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory Share XMerck & Co signs biosimilars deal for US veteranshttps://pharmaphorum.com/news/merck-co-signs-biosimilars-deal-for-us-veterans/
Denmark funds Vertex’s CF drug Orkambi, UK talks deadlockedAs uncertainty hangs over the availability of Vertex’s cystic fibrosis drug in England, the company has signed an Share XDenmark funds Vertex’s CF drug Orkambi, UK talks deadlockedhttps://pharmaphorum.com/news/denmark-funds-vertexs-cf-drug-orkambi-uk-talks-deadlocked/
Lilly pushes into migraine market as Emgality approved in USThe FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group Share XLilly pushes into migraine market as Emgality approved in UShttps://pharmaphorum.com/news/lilly-pushes-into-migraine-market-as-emgality-approved-in-us/
CSL Behring lung drug would cost NHS £8m per patient, says NICENICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it Share XCSL Behring lung drug would cost NHS £8m per patient, says NICEhttps://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/
Patients call for end to CF drug price row at key meetingRepresentatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and Share XPatients call for end to CF drug price row at key meetinghttps://pharmaphorum.com/news/patients-call-for-cf-drug-price-agreement-ahead-of-meeting/
Novartis, Bayer consider appeal as court says Avastin can be used in AMDEngland’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in Share XNovartis, Bayer consider appeal as court says Avastin can be used in AMDhttps://pharmaphorum.com/news/novartis-bayer-consider-appeal-as-court-says-avastin-can-be-used-in-amd/
MPs call for NHS funding for HIV prevention drugLeading UK politicians have called for an HIV prevention drug to be made available across the NHS, after Share XMPs call for NHS funding for HIV prevention drughttps://pharmaphorum.com/news/mps-call-for-nhs-funding-for-hiv-truvada/
Pharma body agrees five-year deal to boost NHS innovationThe UK’s pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), has signed a five-year partnership Share XPharma body agrees five-year deal to boost NHS innovationhttps://pharmaphorum.com/news/abpi-agrees-five-year-deal-to-boost-nhs-innovation/
Mylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedMylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price Share XMylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedhttps://pharmaphorum.com/news/mylan-and-fujifilm-biosimilar-approved/
Truvada ruling could allow cheap HIV prevention in the UKCheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people Share XTruvada ruling could allow cheap HIV prevention in the UKhttps://pharmaphorum.com/news/truvada-ruling-could-allow-cheap-hiv-prevention-in-the-uk/
NICE rejects Novartis’ CAR-T in adult lymphomaNICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive Share XNICE rejects Novartis’ CAR-T in adult lymphomahttps://pharmaphorum.com/news/nice-rejects-novartis-car-t-in-adult-leukaemia/
Sanofi unveils eczema drug data, as regulators mull label expansionSanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema Share XSanofi unveils eczema drug data, as regulators mull label expansionhttps://pharmaphorum.com/news/sanofi-unveils-eczema-drug-data-as-regulators-mull-label-expansion/
FDA approves Teva’s migraine drug, decision due on Lilly’s rivalThe FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns Share XFDA approves Teva’s migraine drug, decision due on Lilly’s rivalhttps://pharmaphorum.com/news/fda-approves-tevas-migraine-drug-decision-due-on-lillys-rival/
